Author

Nicolò Formaggio

Institute of Oncology Research

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:batch correction / integration· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:database / resource· 1 Assay:long-read sequencing· 1

Frequent Co-Authors

Daniela BossiiD· 3 shared Jean-Philippe Paul. TheurillatiD· 3 shared Marco BolisiD· 3 shared Andrea CavalliiD· 2 shared Andrea RinaldiiD· 2 shared Claudio LorenziiD· 2 shared Jacopo SgrignaniiD· 2 shared Matteo PecoraroiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Daniela BossiORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

An integrated, transcript-resolution atlas of prostate cancer progression unmasks associations with oncogenic pathways

Jichang Zhang, Claudio Lorenzi, Daniela Bossi, Simone Nicastri, Matteo Corpetti, Nicolò Formaggio, Jacopo Sgrignani, Andrea Cavalli, Marco Bolis, Jean-Philippe Paul. Theurillat

A transcript-resolution prostate cancer atlas, built by uniformly reprocessing public RNA-seq cohorts, links isoform switches in cancer genes to oncogenic pathway activity and some to CRPC survival.

bioRxiv · Sep 22, 2026 · PreprintCancer Biology✦ In-depth digest

Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output Program in Prostate Cancer

Nicolò Formaggio, Jacopo Sgrignani, Gayathri Thillaiyampalam, Claudio Lorenzi, Giada Andrea Cassanmagnago, Marco Coazzoli, Federico Costanzo, Yanick Uebelhart, Daniela Bossi, Diego Camuzi Cassiano, Andrea Rinaldi, Matteo Pecoraro, Roger Geiger, Raffaella Santoro, Marco Bolis, , Jean-Philippe Paul. Theurillat

This study shows that disrupting FOXA1 and FOXA2 disrupts oncogenic programs in both AR-positive and AR-negative prostate cancers.

Cell Reports · Sep 27, 2025Peer-reviewedCancer Biology

TRIM24 Degradation Counteracts Adaptation to Androgen Receptor Inhibition in Prostate Cancer

Daniela Bossi, Arianna Vallerga, Giuseppe Salfi, Nicolò Formaggio, Valentina Ceserani, Zhang Jichang, Tiziano Bernasocchi, Andrea Rinaldi, Lukas Bubendorf, Simone Mosole, Eva Corey, Marco Bolis, Matteo Pecoraro, Roger Geiger, Wouter R. Karthaus, , Jean-Philippe Paul. Theurillat

This study identifies TRIM24 as a target for preventing prostate cancer progression by degrading it to counteract AR inhibition adaptation and tumor relapse.

bioRxiv · Aug 21, 2025 · PreprintCancer Biology